Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125284433 | 12528443 | 3 | F | 20160809 | 20160705 | 20160824 | EXP | TR-VALIDUS PHARMACEUTICALS LLC-TR-2016VAL002223 | VALIDUS | CADIRCI D, ERKUS ME, ALTIPARMAK IH, AYAS CE, SEZEN Y. AN UNUSUAL CAUSE OF HYPERTENSION IN PREGNANCY: RENOVASCULAR HYPERTENSION. JOURNAL OF HARRAN UNIVERSITY MEDICAL FACULTY. 2016;13 (1):95-8 | 27.00 | YR | F | Y | 0.00000 | 20160824 | MD | TR | TR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125284433 | 12528443 | 1 | PS | METOPROLOL TARTRATE. | METOPROLOL TARTRATE | 1 | 100 MG, UNK | UNKNOWN | 17963 | 100 | MG | TABLET | |||||||
| 125284433 | 12528443 | 2 | SS | METOPROLOL TARTRATE. | METOPROLOL TARTRATE | 1 | 50 MG, 1 X 1 | 17963 | 50 | MG | TABLET | ||||||||
| 125284433 | 12528443 | 3 | SS | FUROSEMIDE. | FUROSEMIDE | 1 | 20 MG, QOD | Y | UNKNOWN | 0 | 20 | MG | |||||||
| 125284433 | 12528443 | 4 | SS | NIFEDIPINE. | NIFEDIPINE | 1 | 10 MG, UNK | UNKNOWN | 0 | 10 | MG | ||||||||
| 125284433 | 12528443 | 5 | SS | NIFEDIPINE. | NIFEDIPINE | 1 | 60 MG, 1 X 1 | UNKNOWN | 0 | 60 | MG | ||||||||
| 125284433 | 12528443 | 6 | SS | DOXAZOSIN | DOXAZOSINDOXAZOSIN MESYLATE | 1 | 8 MG, UNK | Y | UNKNOWN | 0 | 8 | MG | |||||||
| 125284433 | 12528443 | 7 | SS | DOXAZOSIN | DOXAZOSINDOXAZOSIN MESYLATE | 1 | 16 MG, UNK | Y | 0 | 16 | MG | ||||||||
| 125284433 | 12528443 | 8 | SS | DOXAZOSIN | DOXAZOSINDOXAZOSIN MESYLATE | 1 | 8 MG, UNK | Y | 0 | 8 | MG | ||||||||
| 125284433 | 12528443 | 9 | SS | METHYLDOPA. | METHYLDOPA | 1 | 250 MG, 3 X 1 | U | UNKNOWN | 0 | 250 | MG | |||||||
| 125284433 | 12528443 | 10 | SS | METHYLDOPA. | METHYLDOPA | 1 | 250 MG, 4 X 2 | U | UNKNOWN | 0 | 250 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125284433 | 12528443 | 1 | Hypertension |
| 125284433 | 12528443 | 3 | Hypertension |
| 125284433 | 12528443 | 4 | Hypertension |
| 125284433 | 12528443 | 6 | Hypertension |
| 125284433 | 12528443 | 9 | Hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125284433 | 12528443 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125284433 | 12528443 | Hypertension | |
| 125284433 | 12528443 | Maternal exposure during pregnancy |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |